Demo Day under the IP Acceleration Program for Startups (IPAS2019) to be Held

1. Outline of the IPAS program

This program aims to accelerate growth of startups from two viewpoints of business and IP.

For startups, their IP itself, e.g., innovative technologies and ideas, is a source of their competitiveness. Nevertheless, many startups in the earliest stage of business formation are likely to prioritize smooth business operation and drive themselves to advance their business operation without developing any IP strategy, under which they should make use of IP to the maximum extent possible and lead this to business growth. As a result, they are likely to face: leakage of their technologies and ideas, appearance of counterfeit products and failure to make profits associated with IP, which leads to a loss in competitiveness.

Under this program, the JPO creates “IP Mentoring Teams” consisting of business and IP experts with knowledge and skills tailored to challenges and demands for support measures that each startup as the recipient of support measures is facing and needs. An IP Mentoring Team supports such recipients in diagnosing and brushing up its business strategy along with developing an IP strategy..

2. IPAS2019 Demo Day (presentations of IPAS2019 outcomes)

Under the IPAS2019 program, the JPO selected 15 startups out of 111 applicants based on such viewpoints as business feasibility and the needs for IP support and provided them each with a three-month mentoring program. At the Demo Day event, these startups as the recipients of support measures will make presentations about their outcomes from the IPAS2019 program.

Date and time: September 18 (Fri.), 2020; from 16:00 to 18:00

Event style: Online distribution

Program (tentative):

16:00-16:15: Explanations of outline of IPAS (JPO)
16:15-17:00: Part 1: Pitch presentations about outcomes by startups
17:00-18:00: Part 2: Session

Notes:
1. Time schedules of this program may change to some extent.
2. Speakers from companies are under coordination.
How to apply: If you wish to view the event, please complete prior registration on the following website.

• IP Base (in Japanese)

Measures against the novel coronavirus disease

• As one of the measures against the novel coronavirus disease, this event will be held online only.
• Please note that in light of future expansion of the novel coronavirus disease, the program and the event style may change.

List of the selected startups as recipients of support measures under the program (in the order of the Japanese syllabary)

Alivas Inc. (Address: Bunkyo Ward, Tokyo; President: Tajima Tomoyuki)
Development of new medical equipment to treat intractable constipation, aiming to change current situations where treatment means for intractable chronic constipation, which are refractory to drug-based treatments, are limited

AISing Ltd. (Address: Minato Ward, Tokyo; President: Idesawa Junichi)
Development of machines with a built-in AI algorithm providing the characteristics of ultra-lightweight operation, high-speed data processing, real-time learning and a standalone mode

A*Quantum Inc. (Address: Minato Ward, Tokyo; President: Funabashi Koji)
Development of platforms for quantum computers and common libraries

QunaSys Inc. (Address: Bunkyo Ward, Tokyo; President: Yan Tennin)
Development of approaches to commercialization of quantum technology, e.g., quantum computers proactively taking advantage of quantum characteristics, through efforts for spotlighting quantum physics

Spacelink Co., Ltd. (Address: Kawasaki City, Kanagawa Prefecture; President: Abe Akikuni)
Development of Green Capacitor (TM), a device having all of the characteristics of large capacity, quick charging, safety, longer life and low cost

Setsuro Tech Corporation (Address: Tokushima City, Tokushima Prefecture; President: Takezawa Shinichiro)
Development of a method of preparing genetically engineered mice (genome-edited mice) in a simple and highly-efficient manner, making use of a fertilized egg electroporation method

Tsubota Laboratory, Inc. (Address: Shinjuku Ward, Tokyo; President: Tsubota Kazuo)
Keio University-oriented venture business engaging in development of innovative solutions to myopia, dry eye syndrome and presbyopia

BionicM Inc. (Address: Bunkyo Ward, Tokyo; President: Sun Xiaojun)
Development of prosthetic legs for assisting users in moving, to which robot engineering is applied and in which postures or motions of users are recognized by a variety of sensors and control is executed based on bioengineering

Pi-Crystal, Inc. (Address: Kashiwa City, Chiba Prefecture; President: Ito Yosuke, as of the date of providing support measures to the startup)
Manufacturing of soft, thin, lightweight and inexpensive devices by applying organic semiconductor single crystals technology, an outcome of the development by the University of Tokyo

Photo electron Soul Inc. (Address: Nagoya City, Aichi Prefecture; President: Suzuki Takayuki)
Development of electron beam generators taking advantage of semiconductor photocathode technology

Braizon Therapeutics, Inc. (Address: Bunkyo Ward, Tokyo; President: Tosu Mariko)
Research and development of pharmaceuticals, diagnostic pharmaceuticals, research reagents and other products, mainly targeting the central nervous system domain

Metabologenomics, Inc. (Address: Tsuruoka City, Yamagata Prefecture; President: Fukuda Shinji)
Development of a health care service based on different types of intestinal environments in which the startup appropriately categorizes intestinal environments of users, which vary among people, into certain types and provides users with approaches tailored to each type of intestinal environment so that users are able to aim to maintain good health and prevent diseases.

MediGear International Corporation (Address: Yokohama City, Kanagawa Prefecture; President: Tanaka Takeo)
Development of a less invasive cancer therapy, an approach to smoothly achieving medical homogenization without depending on the medical skill levels varying among physicians

UBiENCE Corporation (Address: Chuo Ward, Tokyo; President: Takeuchi Hirofumi)
Research and development of a degradation inducer of a target protein mainly used to meet the indications of cancer and unmet medical needs

• URL: UBiENCE Corporation website

LeapMind Inc. (Address: Shibuya Ward, Tokyo; President: Matsuda Soichi)
Development of software and hardware for deep learning with small, energy-efficient embedded devices

Division in Charge

Policy Planning and Research Division, Policy Planning and Coordination Department, Japan Patent Office